On the last 27th – 28th of October, nearly 50 representatives of TransBioLine consortium met face-to-face in Barcelona for the first time after the pandemic to hold the 5th Consortium Meeting, a 2-day event organised by us.
Even with virtual attendance being offered, around 50 representatives of the TransBioLine consortium had the opportunity to meet again face-to-face to share updates and upcoming project activities. During this 5th TransBioLine Consortium Meeting, organised by us, the participants brainstormed on the project’s sustainability and agreed on the next steps to follow to secure the Project’s legacy. Additionally, other relevant topics like project progression were also approached during this F2F event.
Following two days of fruitful discussions, to close the meeting, the SAB (Scientific Advisory Board) and EAB (Ethical Advisory Board) members provided their feedback and suggestions to achieve the project objectives successfully.
TransBioLine promises a decisive advance in safety biomarker identification, development, and qualification for a more informed decision-making process during drug development, or even later, during the regulatory processes of drug approval, facilitating the evaluation of drug safety: all in all, to streamline drug development and ensure patient safety.
TransBioLine is a project supported by the Innovative Health Initiative, a public-private partnership between the European Union and EFPIA.
For more information visit TransBioLine project website.